Skip to main content

Service

  • SmPC

Main navigation

  • Events &
    Resources
  • AZ Oncology
    Pipeline

Welcome to CALQUENCE.CH

For legal reasons, only medical professionals may receive information on prescription medicines. This area is therefore only available to medical professionals and is password protected.

To access the website, please use the login of Swiss-RX.

Swiss-RX Login TO SWISS-RX LOG IN

Welcome to CALQUENCE.CH

For legal reasons, only medical professionals may receive information on prescription medicines. This area is therefore only available to medical professionals and is password protected.

To access the website, please use the login of Swiss-RX.

Swiss-RX Login TO SWISS-RX LOG IN
AstraZeneca
E-Mail
Do you have any further questions or suggestions?
We look forward to your questions or feedback!

AstraZeneca AG

Responsible according to § 5 TMG
is the company AstraZeneca AG,
Neuhofstrasse 34,
6340 Baar, Schweiz


CH-8901 / 02-2024

Target group

The contents of this website are intended for HCPs from Switzerland.

Sitemap

Home Selectivity & MoA First Line R/R CLL Guidelines
Dosing Events & Resources On demand media AZ Oncology Pipeline

▼ This drug is subject to additional monitoring. For more information, see the Calquence product information on www.swissmedicinfo.ch.

Calquence®

C: Acalabrutinib; film coated tablets containing 100 mg acalabrutinib; List A. I: Mantle cell lymphoma (MCL): As monotherapy for the treatment of adult patients with MCL who have not achieved a partial response with previous therapy or who have shown progression after previous therapy. Chronic lymphocytic leukemia (CLL): As monotherapy or in combination with Obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia CLL who are 65 years of age or older or have comorbidities. As monotherapy for the treatment of adult patients with CLL who have received at least one prior therapy. P: 100 mg (1 tablet) twice daily, taken approximately 12 hours apart, with or without food. For recommended dose adjustments in the event of Grade ≥3 adverse effects: see www.swissmedicinfo.ch. It is not recommended to administer CALQUENCE in patients with severe hepatic impairment CI: Hypersensitivity to the active substance or to any of the excipients. PR: Second primary malignancies, infections, haemorrhages, cytopenia, atrial fibrillation, tumour lysis syndrome (TLS), Hepatotoxicity, including drug-induced liver injury (DILI). IA: Strong CYP3A modulators, substrates of BCRP (Breast Cancer Resistance Protein), substrates of MATE1 (e.g. metformin) AE: Calquence as monotherapy. Very common: Upper respiratory tract infection, sinusitis, pneumonia, second primary malignancy, neutropenia, anaemia, thrombocytopenia, leucopenia, decreased absolute neutrophil count, decreased haemoglobin, decreased platelet count, headache, dizziness/vertigo, bruising, contusion, haemorrhage/haematoma, high blood pressure, cough, diarrhoea, nausea, constipation, Abdominal pain, vomiting, rash, musculoskeletal pain, arthralgia, fatigue. Common: urinary tract infection, nasopharyngitis, bronchitis, herpes virus infections, sepsis, second primary malignancy excluding non-melanoma skin malignancy, non-melanoma skin malignancy, atrial fibrillation/flutter, petechiae, ecchymosis, epistaxis, asthenia. Calquence as combination therapy with other drugs. Very common: upper respiratory tract infection, sinusitis, pneumonia, urinary tract infection, nasopharyngitis, herpes viral infections, second primary malignancy, second primary tumour without non-melanoma skin cancer, neutropenia, anaemia, thrombocytopenia, leukopenia, absolute neutrophil count decreased, haemoglobin decreased, platelet decreased, headache, dizziness/vertigo, bruising, contusion, haemorrhage/haematoma, hypertension, cough, diarrhoea, nausea, constipation, abdominal pain, vomiting, rash, musculoskeletal pain, arthralgia, fatigue, asthenia. Common: bronchitis, sepsis, reactivation of a hepatitis B infection, tumour lysis syndrome, atrial fibrillation/flutter, petechiae, ecchymosis, epistaxis. Uncommon, rarely, very rarely: see www.swissmedicinfo.ch. Information as of January 2025. CH-11149/ 01-2025

Additional Information: www.swissmedicinfo.ch or AstraZeneca AG, Neuhofstrasse 34, 6340 Baar. www.astrazeneca.ch.

Professionals can request the mentioned references from AstraZeneca AG.

Footer menu

  • Data privacy
  • Report side effects
  • Cookie policy
  • Terms of use
  • Contact us